Biomea Fusion’s Icovamenib Shows Promise in Type 2 Diabetes Treatment
Icovamenib shows promise in treating type 2 diabetes, particularly for patients with insulin deficiency or prior GLP-1 therapy failure. The Phase 2 trial demonstrated significant HbA1c reductions with a favorable safety profile.
Biomea Fusion’s Icovamenib Shows Promise in Type 2 Diabetes Treatment Read More »